ADC Development Services for Metastatic Cancer Research

Creative Biolabs offers custom antibody-drug conjugates (ADCs) development services by using various types of linker-payloads to conjugate with antibodies. We will deliver the best antibody and conjugated products with a quick turnaround time. With years of experience in bio-conjugation, we provide stable, sensitive, reproducible antibody-drug conjugates in a time and cost efficient way.

Introduction of Metastatic Cancers

Metastatic cancer or primary cancer refers to cancerous tumor spreading from an initial or primary site to a different or secondary site in the body. Some cancer cells can penetrate the walls of lymphatic or blood vessels to circulate to other sites and tissues through the bloodstream. Thus, the metastasis represents the hallmarks of metastatic cancer and is a key element in cancer staging systems. Metastatic cancers are a type of serious cancer due to its invasion ability to other locations in the body. For many types of cancer, it is also called stage IV (four) cancer once the metastasis happened. Generally, the most common regions for the metastases to occur are the lungs, liver, brain, and bones. Symptoms of metastatic cancer include lymphadenopathy, cough, hemoptysis and dyspnea, hepatomegaly, nausea, jaundice, bone pain, headaches, seizures and vertigo.

Fig.1 In metastasis, cancer cells travel through the blood or lymph system, and form metastatic tumors in other parts of the body.

Current Therapeutic Strategies for Metastatic Cancers

Commonly, once the metastatic cancers occurred and the tumor metastasized to other tissues or organs, the treatment is more difficult and the patient's mortality will increase significantly. The treatments depend on the type of primary cancer, the size and location of the metastases, the patient's situation and the previous treatment types. Therapeutic options for the metastatic cancers include radiosurgery, chemotherapy, radiation therapy, biological therapy, hormone therapy, surgery, or a combination of these interventions ("multimodal therapy").

Besides, some new targeted therapy approaches have been designed particularly the ADCs. For example, LY3076226 is a novel ADC targeting the FGFR3 (fibroblast growth factor receptor 3) which is highly expressed on the tumor cells. LY3076226 consists of a fully human anti-FGFR3 antibody, IMC-D11, linked to a cytotoxic payload, the maytansine-derivative DM4 through a cleavable linker (sulfo-SPDB). Preclinical and clinical trials demonstrated that LY3076226 has powerful antitumor activity, which can bind to the human FGFR3 protein with high affinity, and following internalization to carry the potent cytotoxic drug into tumor cells causing cell cycle arrest and cell death. All results support that LY3076226 ADC based on FGFR3 may confer effective tumor control and is a promising therapy method in patients with metastatic cancers.

Fig.2 Structure of LY3076226. (Bouchard, 2014)

Target of ADC Development for Metastatic Cancers:

Creative Biolabs is dedicated to ADCs development services with minimized structure changes, mild reaction conditions and simple implementation to suit your drug discovery requirement. Our experienced scientists are proficient in optimizing methods of bio-conjugation. Please contact us to discuss your project. We would be happy to provide you with a customized quote.

Reference

1. Bouchard, H.; et al. Antibody-drug conjugates-a new wave of cancer drugs. Bioorganic & medicinal chemistry letters. 2014, 24(23): 5357-5363.

For Research Use Only. NOT FOR CLINICAL USE.